Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
Pageaux GP, Nzinga CL, Ganne N, Samuel D, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, de Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Riachi G, Alric L, Gelu-Simeon M, Minello A, Gournay J, Geist C, Tran A, Abergel A, Portal I, d'Alteroche L, Raffi F, Fontaine H, Carrat F, Pol S; French ANRS CO22 Hepather Cohort. Pageaux GP, et al. Among authors: tran a. BMC Infect Dis. 2022 Jan 27;22(1):94. doi: 10.1186/s12879-022-07076-0. BMC Infect Dis. 2022. PMID: 35086481 Free PMC article.
The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study.
Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, Botta-Fridlund D, Gerolami A, Ouzan D, Halfon P, Zarski JP. Leroy V, et al. Among authors: tran a. Eur J Gastroenterol Hepatol. 2002 May;14(5):485-9. doi: 10.1097/00042737-200205000-00004. Eur J Gastroenterol Hepatol. 2002. PMID: 11984145 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. Among authors: tran a. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis.
Abergel A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, de Ledinghen V, Canva V, Bronowicki JP, Tran A, Martineau N, Lafeuille H, Dechelotte P, Bommelaer G, Bonny C; French Multicentre Study Group. Abergel A, et al. Among authors: tran a. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1219-27. doi: 10.1097/00042737-200411000-00022. Eur J Gastroenterol Hepatol. 2004. PMID: 15489585 Clinical Trial.
Serum fibrosis markers can detect large oesophageal varices with a high accuracy.
Vanbiervliet G, Barjoan-Mariné E, Anty R, Piche T, Hastier P, Rakotoarisoa C, Benzaken S, Rampal P, Tran A. Vanbiervliet G, et al. Among authors: tran a. Eur J Gastroenterol Hepatol. 2005 Mar;17(3):333-8. doi: 10.1097/00042737-200503000-00012. Eur J Gastroenterol Hepatol. 2005. PMID: 15716658
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.
Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D. Halfon P, et al. Among authors: tran a. Am J Gastroenterol. 2006 Mar;101(3):547-55. doi: 10.1111/j.1572-0241.2006.00411.x. Am J Gastroenterol. 2006. PMID: 16542291
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Bronowicki JP, et al. Among authors: tran a. Gastroenterology. 2006 Oct;131(4):1040-8. doi: 10.1053/j.gastro.2006.07.022. Epub 2006 Jul 24. Gastroenterology. 2006. PMID: 17030174 Clinical Trial.
2,192 results